Gear Up for Idexx (IDXX) Q3 Earnings: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Idexx (IDXX) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research • Oct 28, 2026

Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 26, 2026

Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings

IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.

Zacks Investment Research • Oct 23, 2026

Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 20, 2026

Idexx (IDXX) Moves to Buy: Rationale Behind the Upgrade

Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Oct 19, 2026

IDEXX Laboratories to Release 2026 Third Quarter Financial Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX websi.

Business Wire • Oct 1, 2026

Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories

Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicle CHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX).

PRNewsWire • Sep 30, 2026

Should You Continue to Hold IDXX Stock in Your Portfolio?

IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.

Zacks Investment Research • Sep 23, 2026

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

IDEXX Laboratories NASDAQ: IDXX executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers.

MarketBeat • Sep 20, 2026

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

IDEXX Laboratories NASDAQ: IDXX executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits.

MarketBeat • Sep 20, 2026